OAKLAND PARK, FL--(Marketwired - Jan 28, 2016) - (OTC PINK: BSEM), Biostem Technologies, Inc. We are pleased to announce that Biostem Technologies, Inc. has entered into an agreement with Dr. Jesus Esparragoza Romano and his team in Guadalajara, Mexico to form the Mexican entity -- Bio ST Holdings, S. de R.L. de C.V. which is a wholly owned subsidiary of Biostem Technologies, Inc.
Biostem Technologies, Inc. is also proudly announcing the addition of cardiologist, Dr. Jesus Esparragoza Romano, as its Chief Medical Advisor of Bio ST Holdings, S. de R.L. de C.V. Dr. Esparragoza, M.D. is a Fellow of American College of Cardiology who graduated from the Faculty of Medicine of the University Autónoma de Guadalajara in 1977, and acquired the title of Doctor Surgeon; then, in 1979 studied an intensive course of medicine at the Oakland University in Rochester, Michigan. He went on to complete his studies of Internal Medicine specializing in Cardiology at the Centro Médico de Occidente Hospital at Guadalajara, Jalisco where in conjunction with several doctors, performed the first heart transplant. Dr. Esparragoza also consults with the adult services program at the Heart Institute for Cardiology in Houston Texas and is a certified member of interventional Cardiology by SOCIME (Society of Interventional Cardiology of México). He has been working with adult stem cells for over 8 years now.
As part of the agreement Dr. Jesus Esparragoza Romano and Jesus Esparragoza Fox were issued 200,000 shares of restricted common stock and will retain 30% of adjusted net income from services performed through Bio ST Holdings, S. de R.L. de C.V.
CEO Jason Matuszewski stated, "We have evaluated several different physicians and facilities. Based on quality of care and medical staff/personnel, we believe that Dr. Esparragoza, who works at the San Javier Hospital, has exceeded our expectations for medical care and would be an asset to our team. We look forward to working with him in the stem cell sector."
About Biostem Technologies, Inc. (OTC PINK: BSEM):
Biostem Technologies (BSEM) is engaged in the advancement of regenerative medicine and anti-aging strategies throughout the United States, Europe, and Mexico. BSEM's goal is to deliver the highest standard of wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using the highest quality nutraceuticals and stem cells. Our quest is to introduce the world, and our shareholders to our dedication to you and your well-being.
Mission Statement - Biostem Technologies, Inc. is a Global Leader in Anti-Aging research. We are focused on advancing your quality of life, health span, and wellness.
Vision Statement - Biostem Technologies, Inc. is a group of scientists, physicians, and visionaries creating the possibility of living life to its fullest. Our products and strategies are dedicated to helping you live your best, feel your best, and be your best.
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," "believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.